Very‐high frequency plasmapheresis and donor health–absence of evidence is not equal to evidence of absence.

The article discusses the growing utilization of Plasma-Derived Medicinal Products (PDMPs) and the importance of ensuring the safety of plasma donors. It critiques two studies that concluded that repeated plasmapheresis (plasma donation) is safe for donors, pointing out methodological shortcomings and selection biases in the studies. The authors argue that more robust evidence, such as randomized controlled trials (RCTs) and real-world data analysis, is needed to determine the long-term impact of repeated plasmapheresis on donor health. They emphasize the need for trustworthy evidence syntheses and transparent criteria for evaluating the quality of evidence. Until more conclusive evidence is available, blood establishments will continue to prioritize donor safety. [Extracted from the article]